[144] Vital Farms, Inc. SEC Filing
Vital Farms insider sale notice: The filing reports a proposed sale of 125,000 common shares through Morgan Stanley Smith Barney with an aggregate market value of $5,482,500, scheduled for 08/08/2025 on NASDAQ. The shares were acquired as founders shares on 01/16/2015.
The filing also lists prior 10b5-1 sales attributed to Matthew Ohayer totaling 124,000 shares that generated $4,482,436.50 across seven transactions between 05/19/2025 and 08/07/2025. The proposed 125,000-share sale represents approximately 0.28% of the 44,685,980 shares outstanding.
- Filing discloses a clear plan to sell 125,000 common shares with an aggregate market value of $5,482,500.
- The shares were acquired as founders shares on 01/16/2015, which is explicitly documented.
- Recent activity shows orderly dispositions under 10b5-1 arrangements totaling 124,000 shares for $4,482,436.50 in the past three months.
- The proposed sale of 125,000 shares equals roughly 0.28% of outstanding shares (44,685,980) and increases insider liquidation volume.
- Significant insider selling occurred recently: 124,000 shares sold across seven transactions from 05/19/2025 to 08/07/2025.
Insights
TL;DR: Routine Rule 144 disclosure showing ongoing 10b5-1 activity; proposed sale is modest relative to market cap.
The Form 144 documents a planned disposition of 125,000 common shares via Morgan Stanley with an aggregate market value of $5.48M, and confirms these were acquired as founders shares on 01/16/2015. Recent 10b5-1 sales total 124,000 shares for $4.48M in the prior three months, indicating active, prearranged selling rather than ad hoc offloads. At ~0.28% of outstanding shares, the single proposed sale is unlikely to meaningfully change capitalization but is material as an insider liquidity event to track.
TL;DR: Disclosure is standard for insiders selling under Rule 144 and 10b5-1 plans; no governance red flags in this filing alone.
The notice names a broker and provides acquisition detail (founders shares dated 01/16/2015), complying with Rule 144 disclosure norms. The series of 10b5-1 transactions listed demonstrates use of written trading plans or instructions. There is no allegation of undisclosed material information in the filing; however, stakeholders may monitor cumulative insider selling for context alongside other company disclosures.